Ranolazine + Placebo

ApprovedCompleted

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Microvascular Angina

Conditions

Microvascular Angina

Trial Timeline

Apr 1, 2014 → Nov 1, 2015

NCT ID

NCT02052011

About Ranolazine + Placebo

Ranolazine + Placebo is a approved stage product being developed by Gilead Sciences for Microvascular Angina. The current trial status is completed. This product is registered under clinical trial identifier NCT02052011. Target conditions include Microvascular Angina.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (18)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03044964	Approved	UNKNOWN	Jan 10, 2017	Oct 1, 2017	Angina
NCT02829034	Approved	Completed	Jul 1, 2016	Jan 1, 2018	Pulmonary Hypertension
NCT02423265	Approved	Withdrawn	Jun 1, 2015	Mar 1, 2017	Myocardial Ischemia
NCT02147067	Phase 2	Completed	Sep 1, 2014	Jun 1, 2018	Microvascular Angina
NCT02156336	Approved	Terminated	May 1, 2014	Feb 8, 2017	Diabetic Peripheral Neuropathic Pain
NCT02052011	Approved	Completed	Apr 1, 2014	Nov 1, 2015	Microvascular Angina
NCT01948310	Approved	Completed	Dec 1, 2013	Oct 10, 2016	Chronic Stable Angina
NCT01887353	Phase 2	Terminated	Jun 1, 2013	Feb 1, 2014	Atrial Fibrillation
NCT01767987	Phase 2	Terminated	Nov 1, 2012	Apr 1, 2014	Acute Coronary Syndrome
NCT01590979	Pre-clinical	Terminated	Apr 1, 2012	Jun 1, 2015	Atrial Fibrillation New Onset
NCT01558830	Approved	UNKNOWN	Jan 1, 2012	Jul 1, 2013	Chronic Stable Angina
NCT01472185	Phase 3	Completed	Nov 1, 2011	Oct 1, 2013	Type 2 Diabetes Mellitus
NCT01442038	Phase 3	Completed	Oct 1, 2011	Feb 1, 2015	Coronary Artery Disease
NCT01505179	Pre-clinical	Completed	Feb 1, 2011	Jan 1, 2015	Heart Failure With Preserved Ejection Fraction
NCT01352416	Phase 3	Terminated	Sep 1, 2010	Nov 1, 2012	Heart; Dysfunction Postoperative, Cardiac Surgery
NCT01163721	Phase 2	Completed	Jun 1, 2010	Nov 1, 2010	Diabetes Mellitus, Type 2
NCT00832572	Approved	Terminated	Jan 1, 2009	Jun 1, 2009	Coronary Artery Disease
NCT00099788	Phase 3	Completed	Oct 1, 2004	Feb 1, 2007	Myocardial Ischemia

Competing Products

7 competing products in Microvascular Angina

See all competitors

Product	Company	Stage	Hype Score
Zibotentan + Placebo oral tablet	AstraZeneca	Phase 2	52
Lercanidipine + Valsartan + Nicorandil + Doxazosin + Moxonidin + Pindolol + Amiloride, hydrochlorothiazide	Novartis	Pre-clinical	23
Ranolazine + Placebo	Gilead Sciences	Phase 2	51
Temanogrel + Placebo	Pfizer	Phase 2	51
SAR247799 + Placebo + Sildenafil + Acetylcholine	Sanofi	Phase 1	32
SAR407899 + Placebo + Adenosine + Regadenoson + 13N-ammonia + 82Rubidium	Sanofi	Phase 2	51
Felzartamab + Placebo	Biogen	Phase 2	49

Other Products from Gilead Sciences

Truvada + Atazanavir + RitonavirApproved

Truvada + efavirenzApproved

B/F/TAF + Atripla + B/F/TAF Placebo + Atripla PlaceboApproved

TDF + Placebo Vaginal Gel + Vaginal TFV Gel + Placebo TabletsApproved

B/F/TAFApproved